Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression - Inhibitory effects of anti-inflammatory drugs

Journal of Allergy and Clinical Immunology

Volumn 105, Issue 3, 2000, Pages 552-560

  Wedi, Bettina ^a   Novacovic, Vera ^a   Koerner, Michael ^a   Kapp, Alexander ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTOANTIBODY; CD63 ANTIGEN; CHLOROQUINE; DAPSONE; HISTAMINE; IMMUNOGLOBULIN E RECEPTOR; LEUKOTRIENE; LIDOCAINE; MIZOLASTINE; PEPTIDOLEUKOTRIENE;

ARTICLE; BASOPHIL; CHRONIC URTICARIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0034123988     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.104939     Document Type: Article

References (61)

1. 1. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999;140:667-71.
2. 2. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 1997;133:1003-8.
3. 3. Di Campli C, Gasbarrini A, Nucera E, Franceschi C, Ojetti V, Sanz Torre E, et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998; 43:1226-9.
4. 4. Valsecchi R, Pigatto P. Chronic urticaria and Helicobacter pylori. Acta Derm Venereol 1998;78:440-2.
5. 5. Wedi B, Wagner S, Werfel T, Manns MP, Kapp A. Prevalence of Helicobacter pylori associated gastritis in chronic urticaria. Int Arch Allergy Immunol 1998; 116:288-94.
6. 6. Wedi B, Elsner J, Kapp A. In vitro diagnostic of pseudoallergic reactions - new aspects. Allergy Clin Immunol Intern 1996;8:113-5.
7. 7. Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria: a prospective study. Acta Derm Venereol 1995;75:484-7.
8. 8. Leznoff A, Josse RG, Denburg J, Dolovich J. Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 1983;119:636-40.
9. 9. Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21:695-704.
10. 10. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988;90:213-7.
11. α (α-subunit) in chronic urticaria. J Allergy Clin Immunol 1998;101:672-6.
12. 12. Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders: identification of a structure-function relationship. J Clin Invest 1998;101:243-51.
13. 13. Greaves MW, O'Donnell BF. Not all chronic urticaria is "idiopathic"! Exp Dermatol 1998;7:11-3.
14. 14. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996;106:1001-6.
15. 15. Tong LJ, Balakrishnan G, Kochan JP, Kinet JP, Kaplan AP. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997;99:461-5.
16. 16. Hide M, Francis DM, Graltan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328:1599-604.
17. 17. Horn MP, Gerster T, Ochensberger B, Derer T, Kricek F, Jouvin M-H, et al. Human anti-FcεRIα autoantibodies isolated from healthy donors cross-react with tetanus toxoid. Eur J Immunol 1999;29:1139-48.
18. 18. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchere E, Coutinho A, et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 1998;216:117-37.
19. 19. Mouthon L, Haury M, Lacroix-Desmazes S, Barreau C, Coutinho A, Kazatchkine MD. Analysis of the normal human IgG antibody repertoire: evidence that IgG autoantibodies of healthy adults rccognize a limited and conserved set of protein antigens in homologous tissues. J Immunol 1995;154:5769-78.
20. 20. Grattan CEH, Francis DM, Slater NGP, Barlow RJ, Greaves MW. Plasmapheresis for severe, unremitting, chronic urticaria. Allerg Immunol (Paris) 1992;339:1078-80.
21. 21. O'Donnell BF, Barr RM, Black AK, Francis DM, Kermani F, Niimi N, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998;138:101-6.
22. 22. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104(1 Suppl):3-9.
23. 23. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991;88:328-38.
24. 24. Koyama Y, Suzuki M, Yoshida T. CD63, a member of tetrapsan transmembrane protein family, induces cellular spreading by reaction with monoclonal antibody on substrata. Biochem Biophys Res Commun 1998;246:841-6.
25. 25. Rubinstein E, Le Naour F, Lagaudrière Gesbert C, Billard M, Conjeaud H, Boucheix C. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 1996;26:2657-65.
26. 26. Moneret-Vautrin DA, Sainte-Laudy J, Kanny G, Frémont S. Human basophil activation measured by CD63 expression and LTC4 release in IgE-mediated food allergy. Ann Allergy Asthma Immunol 1999;82:33-40.
27. 27. Sainte-Laudy J, Sabbah A, Vallon C, Guerin JC. Analysis of anti-IgE and allergen induced human basophil activation by flow cytometry: comparison with histamine release. Inflamm Res 1998;47:401-8.
28. 28. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990;323:645-55.
29. 29. Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration of arachidonic acid-induced cutanwous reactions in the rat. Arzneimittelforschung 1998;48:179-84.
30. 30. Nürnberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol (Stockh) 1995;75:54-6.
31. 31. Wisnieski JJ, Baer AN, Christensen J, et al. Hypocomplementemic urticarial vasculitis syndrome: clinical and serologic findings in 18 patients. Medicine 1995;74:24-41.
32. 32. Fortson JS, Zone JJ, Hammond ME, Groggel GC. Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone. J Am Acad Dermatol 1976;15:1137-42.
33. 33. Ohnishi T, Kita H, Mayeno AN, Okada S, Sur S, Broide DH, et al. Lidocaine in bronchoalveolar lavage fluid (BALF) is an inibitor of eosinophil-active cytokines. Clin Exp Immunol 1996;104:325-31.
34. 34. Decco ML, Neeno TA, Hunt LW, O'Connell EJO, Yunginger JW, Sachs MI. Nebulized lidocaine in the treatment of severe asthma in children: a pilot study. Ann Allergy Asthma Immunol 1999;82:29-32.
35. 35. Zweiman B, Valenzano M, Atkins PC, Tanus T, Getsy J. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 1996;98:89-98.
36. 36. Knol EF, Mul FP, Lie WJ, Verhoeven AJ, Roos D. The role of basophils in allergic disease. Eur Respir J Suppl 1996;22:126-31s.
37. 37. Gibbs BF, Amon U, Pearce FL. Spontaneous histamine release from mast cells and basophils is controlled by the cellular environment. Inflamm Res 1997;46(1 Suppl):S25-6.
38. 38. Warner JA, Peters SP, Lichtenstein LM, Hubbard W, Yancey KB, Stevenson HC, et al. Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli. J LeuKoc Biol 1989;45:558-62.
39. 39. Sabroe RA, Seed PT, Francis DM, Barr RM, Kobza-Black A, Greaves MW. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FceRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999;40:443-50.
40. 40. Leynadier F, Bousquet J, Murrieta M, et al. Efficacy and safety of mizolastine in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;76:163-8.
41. 41. Brostoff J, Fitzharris P, Dunmore C, et al. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. J Immunol 1996;51:320-5.
42. 42. Okada S, Hagan JB, Kato M, Bankers-Fulbright JL, Hunt LW, Gleich GJ, et al. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J Immunol 1998;160:4010-7.
43. 43. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 1994;265:1724-8.
44. 44. Grindulis KA, McConkey B. Rheumatoid arthritis: the effects of treatment with dapsone on haemoglobin. J Rheumatol 1984;11:776-8.
45. 45. Person JR, Rogers RS. Bullous pemphigoid responding to sufapyridine and the sulfones. Arch Dermatol 1977;113:610-5.
46. 46. Cooney T, Doyle CT, Buckley D, Whelton MJ. Dermatitis herpetiformis: a comparative assessment of skin and bowel abnormality. J Clin Pathol 1977;30:976-80.
47. 47. Millar BW, Macdonald KJ, Macleod TM, Raffle EJ. Dapsone and human polymorphonuclear leucocyte chemotaxis in dermatitis herpetiformis. Acta Derm Venereol 1984;64:433-6.
48. 48. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993;129:507-13.
49. 49. Anderson R. Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes in vitro. Antimicrob Agents Chemother 1985;27:257-62.
50. 50. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992;98:135-40.
51. 51. Coleman MD, Smith JK, Perris AD, Buck NS, Seydel JK. Studies on the inhibitory effects of analogues of dapsone on neutrophil function in vitro. J Pharm Pharmacol 1997;49:53-7.
52. 52. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997;62: 827-36.
53. 53. Haas N, Toppe E, Henz BM. Microscopic morphology of different types of urticaria. Arch Dermatol 1998;134:41-6.
54. 54. Toppe E, Haas N, Henz BM. Neutrophilic urticaria: clinical features, histological changes and possible mechanisms. Br J Dermatol 1998;138:248-53.
55. 55. Cox NH, Friedmann PS. Induction of lesions of dermatitis herpetiformis by autologous serum. Br J Dermatol 1991;124:69-73.
56. 56. Nishimura M, Hidaka N, Akaza T, Tadokoro K, Juji T. Immunosuppressive effects of chloroquine: potential effectiveness for treatment of posttransfusion graft-versus-host disease. Transfus Med 1998;8:209-14.
57. 57. Schultz KR, Nelson D, Bader S. Synergy between lysomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. Bone Marrow Transplant 1996;18:625-31.
58. 58. Sasaki R, Furukawa Y, Okada K, Nakamura M, Yamane Y, Miura Y, et al. Chloroquine induces basophilic differentiation of HL-60 cells. Leukemia 1997;11(3 Suppl):478-9.
59. 59. Hurst NP, French JK, Gorjatschko L, Betts WH. Studies on the mechanism of inhibition of chemotactic tripeptide stimulated human neutrophil polymorphonuclear leukocyte superoxide production by chloroquine and hydroxychloroquine. Ann Rheum Dis 1987;46:750-6.
60. 60. Krogstad D, Schlesinger P. Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum. N Engl J Med 1987;317:542-9.
61. 61. Charous BL, Halpern EF, Steven GC. Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. J Allergy Clin Immunol 1998;102:198-203.